Date: 2015-05-18
Type of information: Grant
Company: Oryzon Genomics (Spain)
Investors: The Alzheimer’s Drug Discovery Foundation (ADDF) (USA - NY)
Amount: $270,000
Funding type: grant
Planned used: The grant will be used for continued development of Oryzon Genomics\' ORY-2001, a dual LSD1-MAOB inhibitor, as a new therapeutic approach for Alzheimer’s disease. The ADDF award will fund work to finalize the preclinical toxicological characterization needed to move ORY-2001 to clinical stage this year. This drug candidate targets the enzyme LSD1, a histone demethylase which plays a role in regulating the expression of crucial genes that neurons need to stay alive. LSD1 is able to switch the expression of those genes on and off in the neurons in response to age, insults and environmental conditions. LSD1 also regulates the expression of genes involved in the progression of AD and other neurological disorders, such as Parkinson´s and Huntington’s diseases. In 2011, ADDF awarded Oryzon with $300,000 to achieve proof-of-concept for the LSD1 mechanism in AD mouse models. More than two years of extensive research have demonstrated that ORY-2001 is able to stop the disease progression in SAMP-8 mice, a model for accelerated aging and AD. Chronic oral treatment with ORY-2001 for two or four months prevents the development of memory deficits while maintaining an optimal safety profile.
Others: * On May 18, 2015, Oryzon Genomics, an epigenetics-based biotechnology company focused on developing therapeutics in oncology and neurodegenerative diseases, announced that The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded a $270,000 grant to the company for continued development of its molecule ORY-2001, a dual LSD1-MAOB inhibitor, as a new therapeutic approach for Alzheimer’s disease (AD). In 2011, ADDF awarded Oryzon with $300,000 to achieve proof-of-concept for the LSD1 mechanism in AD mouse models. More than two years of extensive research have demonstrated that ORY-2001 is able to stop the disease progression in SAMP-8 mice, a model for accelerated aging and AD.
Therapeutic area: Neurodegenerative diseases
